Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Return on Sales (2016 - 2025)

Corcept Therapeutics' Return on Sales history spans 10 years, with the latest figure at 0.12% for Q4 2025.

  • For Q4 2025, Return on Sales fell 5.0% year-over-year to 0.12%; the TTM value through Dec 2025 reached 0.13%, down 8.0%, while the annual FY2025 figure was 0.13%, 8.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.12% at Corcept Therapeutics, up from 0.09% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.34% in Q3 2022 and bottomed at 0.09% in Q3 2025.
  • The 5-year median for Return on Sales is 0.23% (2023), against an average of 0.22%.
  • The largest annual shift saw Return on Sales rose 7bps in 2021 before it dropped -16bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.32% in 2021, then plummeted by -50bps to 0.16% in 2022, then soared by 44bps to 0.23% in 2023, then dropped by -27bps to 0.17% in 2024, then fell by -29bps to 0.12% in 2025.
  • Per Business Quant, the three most recent readings for CORT's Return on Sales are 0.12% (Q4 2025), 0.09% (Q3 2025), and 0.18% (Q2 2025).